VEA
CRNX icon

Virtus ETF Advisers’s Crinetics Pharmaceuticals CRNX Stock Holding History

Virtus ETF Advisers’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,279
Closed -$65.4K – 513
2024
Q4 		$65.4K Sell
1,279
-683
-35% -$38.2K 0.03% 415
2024
Q3 		$100K Buy
1,962
+31
+2% +$1.6K 0.05% 375
2024
Q2 		$86.5K Sell
1,931
-548
-22% -$25.3K 0.04% 377
2024
Q1 		$116K Sell
2,479
-175
-7% -$6.85K 0.06% 349
2023
Q4 		$94.4K Sell
2,654
-2,195
-45% -$67.3K 0.06% 387
2023
Q3 		$144K Sell
4,849
-484
-9% -$9.97K 0.09% 313
2023
Q2 		$96.1K Sell
5,333
-882
-14% -$17.6K 0.06% 404
2023
Q1 		$99.8K Sell
6,215
-2,383
-28% -$44.1K 0.05% 340
2022
Q4 		$157K Buy
8,598
+2,370
+38% +$41.8K 0.08% 332
2022
Q3 		$122K Buy
6,228
+48
+0.8% +$979 0.05% 395
2022
Q2 		$115K Sell
6,180
-166
-3% -$3.31K 0.04% 396
2022
Q1 		$139K Sell
6,346
-380
-6% -$7.69K 0.06% 239
2021
Q4 		$191K Sell
6,726
-4,499
-40% -$111K 0.07% 225
2021
Q3 		$236K Sell
11,225
-585
-5% -$12.2K 0.1% 226
2021
Q2 		$223K Sell
11,810
-10,072
-46% -$177K 0.09% 266
2021
Q1 		$334K Buy
21,882
+395
+2% +$6.12K 0.14% 218
2020
Q4 		$303K Buy
21,487
+2,116
+11% +$29.5K 0.13% 205
2020
Q3 		$304K Sell
19,371
-2,655
-12% -$40.6K 0.16% 218
2020
Q2 		$386K Buy
+22,026
New +$375K 0.18% 212
2019
Q2 		– Sell
-7,934
Closed -$181K – 438
2019
Q1 		$181K Sell
7,934
-1,100
-12% -$27K 0.39% 92
2018
Q4 		$271K Buy
+9,034
New +$254K 0.05% 143

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Virtus ETF Advisers's CRNX Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2025, closing a stake of 1,279 shares — an estimated $65.4K sold.

Virtus ETF Advisers first reported a position in CRNX in Q4 2018 and held it in 21 quarters. The position peaked at $386K in Q2 2020. 227 funds tracked by Wall St. Rank hold CRNX as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Crinetics Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 1,279 Crinetics Pharmaceuticals shares in Q1 2025, an estimated $65.4K.
  • Virtus ETF Advisers first reported a position in Crinetics Pharmaceuticals in Q4 2018 and held it in 21 quarters.
  • Virtus ETF Advisers's Crinetics Pharmaceuticals position peaked at $386K in Q2 2020.
  • 227 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.